CAS 1821428-35-6

AZD0156

CAS: 1821428-35-6

AZD0156

Fórmula: C₂₆H₃₁N₅O₃

Pureza: 99%

Cor e Forma: Solid

Peso molecular: 461.55604

Ref: 54-BISN0034

2H-Imidazo[4,5-c]quinolin-2-one, 8-[6-[3-(dimethylamino)propoxy]-3-pyridinyl]-1,3-dihydro-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-

CAS: 1821428-35-6

Fórmula: C₂₆H₃₁N₅O₃

Pureza: 99%

Cor e Forma: Solid

Peso molecular: 461.5560

Ref: IN-DA0023ET

AZD0156

CAS: 1821428-35-6

AZD0156

Fórmula: C₂₆H₃₁N₅O₃

Pureza: ≥98%

Peso molecular: 461.56

Ref: 54-BUP02564

AZD0156

CAS: 1821428-35-6

AZD0156 , an effective and specific inhibitors of ATM kinase, is potential antineoplastic activities and chemo-/radio-sensitizing.

Fórmula: C₂₆H₃₁N₅O₃

Pureza: 99.13% - 99.87%

Cor e Forma: Solid

Peso molecular: 461.56

Ref: TM-T6770

AZD0156

CAS: 1821428-35-6

8-(6-(3-(Dimethylamino)propoxy)pyridin-3-yl)-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]quinolin-2(3H)-one

Fórmula: C₂₆H₃₁N₅O₃

Pureza: 99%

Peso molecular: 461.56

Ref: IN-DG759419

AZD 0156

Produto Controlado

CAS: 1821428-35-6

Fórmula: C₂₆H₃₁N₅O₃

Cor e Forma: Neat

Peso molecular: 461.556

Ref: TR-A216040

AZD0156

CAS: 1821428-35-6

AZD0156 is a novel anticancer drug. It is an inhibitor of the receptor tyrosine kinase, RET, which is involved in the development of a variety of cancers. AZD0156 has been shown to have cytostatic effects on a number of cancer cell lines and to be effective in treating adrenocortical carcinoma. This drug also exhibits pharmacokinetic properties that allow it to be delivered orally or intravenously and has been shown to selectively inhibit RET-mediated signals. It interacts with RET receptors, causing inhibition of downstream signaling events that are mediated by this receptor. These events include cell proliferation, migration, and survival.

Fórmula: C₂₆H₃₁N₅O₃

Pureza: Min. 95%

Peso molecular: 461.56 g/mol

Ref: 3D-WXC42835

Olaparib Impurity 36

CAS: 1821428-35-6

Fórmula: C₂₆H₃₁N₅O₃

Peso molecular: 461.57

Ref: ST-EA-CP-O6034